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Abstract
Background: The roll-out of antiretroviral therapy (ART) in Africa will have significant resource
implications arising from its impact on demand for healthcare services. Existing studies of
healthcare utilization on HAART have been conducted in the developed world, where HAART is
commenced when HIV illness is less advanced.
Methods: This paper describes healthcare utilization from program entry by treatment-naïve
patients in a peri-urban settlement in South Africa. Treatment criteria included a CD4 cell count
<200 cells/µl or an AIDS-defining illness. Data on health service utilization were collected
retrospectively from the primary-care clinic and secondary and tertiary referral hospitals. Hospital
visits were reviewed to determine the clinical reason for each visit.
Results: 212 patients were followed for a median of 490 days. Outpatient visits per 100 patient
years of observation (PYO), excluding scheduled primary-care follow-up, fell from 596 immediately
prior to ART to 334 in the first 48 weeks on therapy and 245 thereafter. Total inpatient time fell
from 2,549 days per 100 PYO pre-ART to 476 in the first 48 weeks on therapy and 73 thereafter.
This fall in healthcare utilization occurred at every level of care. The greatest causes of utilization
were tuberculosis, cryptococcal meningitis, HIV-related neoplasms and adverse reactions to
stavudine. After 48 weeks on ART demand reverted to primarily non-HIV-related causes.
Conclusion: Utilization of both inpatient and outpatient hospital services fell significantly after
commencement of ART for South African patients in the public sector, with inpatient demand
falling fastest. Earlier initiation might reduce early on-ART utilization rates.
Background
The past two years have seen the rapid expansion of access
to highly-active antiretroviral therapy (ART) worldwide,
with the aim of treating all 6.5 million people who are
estimated to need treatment [1]. South Africa has also
seen a rapid expansion of those taking antiretrovirals
through the public sector since the public sector ART pro-
gram was begun in 2004 [2]. It has been argued that the
most pressing constraint on the progress of this expansion
of access will be a lack of healthcare personnel and other
resources [3,4], but there remains little evidence on the
impact of ART provision on healthcare utilization in set-
tings where HIV is a significant burden on the healthcare
system [5,6].
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A large proportion of those accessing healthcare in the
public sector in Africa are HIV positive. In 1992, 39% of
patients at the main tertiary referral hospital in Nairobi
were HIV positive, and by 1997 this had risen to 70% of
medical admissions [7,8]. Studies in South Africa found
that the number and proportion of patients being admit-
ted for diagnoses often linked to advanced HIV-related
disease increased considerably between 1991 and 2002
[9], and that inpatient seroprevalence rates were over 50%
in Durban by 1998 [10]. Information on the use of serv-
ices both prior to and after the commencement of ART,
and by patients at different stages of illness, is needed to
accurately predict future resource needs.
This increased burden of acute illness due to HIV has
placed significant strain on healthcare systems in the
region. The experience of North America was that the
advent of ART led to a fall in demand for inpatient care
[11-14]. Its effect on demand for outpatient care is
unclear, with some studies finding an increase in demand
[11,12], while others found a decrease [13,14]. One study
noted that the decrease in inpatient demand was particu-
larly steep for HIV-related inpatient stays [14]. These
changes are likely to have been due to reduced need to
treat opportunistic infections (OIs) [15]. A recent hospi-
tal-based study of the cost-effectiveness of ART in South
Africa found a partial offsetting of additional medicine
costs for ART by reduced hospital inpatient stays and out-
patient visits [16].
There has to date, however, been no research on health-
care utilization at the commencement of ART in Africa. In
more developed nations commencement of antiretrovi-
rals is not associated with severe illness or with significant
changes in overall healthcare utilization. Data from such
settings are unlikely to be predictive of utilization rates in
Africa, however, since patients in richer nations com-
mence ART far earlier in the HIV disease process, avoiding
the potential for high levels of mortality and morbidity
associated with commencing ART at CD4 counts under
100 cells/µl [17,18].
The aim of this study is to assess patterns of healthcare uti-
lization seen as severely immune-suppressed persons
begin ART at a primary-care clinic in Africa. This informa-
tion will contribute to the planning of healthcare provi-
sion as access to antiretrovirals is expanded.
Methods
Data collection
The Hannan Crusaid Treatment Centre (HCTC) is a dedi-
cated, public-sector antiretroviral clinic in a peri-urban
settlement near Cape Town, South Africa. The site began
recruitment in September 2002, and its work has been
previously described [19]. For those enrolled at the centre,
the HCTC acts as their primary health care facility, dis-
pensing ART and providing treatment for HIV-related OIs
and other illnesses.
Patients are referred by local primary-care providers based
on CD4 lymphocyte count or clinical symptoms of AIDS.
They are screened at the HCTC and seen a second time 14
days later, prior to commencing ART. Patients then attend
scheduled visits at 0, 4, 8 and 16 weeks after commence-
ment, and every 16 weeks thereafter. Patients may make
unlimited unscheduled visits to the HCTC as required.
Any referrals to higher levels of the public health system
are recorded, and patients are referred back to the HCTC
after such care has been received. All public-sector care is
free at the point of service, although non-primary utiliza-
tion requires a referral in order to qualify for this.
The study population was eligible patients who enrolled
in the program prior to January 2004. In line with
national guidelines eligibility criteria were a CD4 count of
less than 200 cells/µl or an AIDS-defining illness [20]. In
addition, the HCTC required a local residential address,
attendance of three treatment education sessions and dis-
closure to at least one friend or relative. All subjects were
followed-up for a minimum of 48 weeks or to censor;
those who commenced antiretroviral therapy prior to
October 2003 were additionally followed until their final
scheduled four-monthly visit prior to January 2005.
Patients were right censored for death, loss to follow-up or
transfer to another ART site.
The primary regimen was non-nucleoside reverse tran-
scriptase (NNRTI) based and consisted of stavudine, lam-
ivudine and efavirenz (or nevirapine if pregnancy was
likely). In the case of virological failure or of adverse reac-
tion a secondary, protease inhibitor (PI) based regimen of
zidovudine, didanosine and lopinavir/ritonavir was pro-
vided.
Data on patient-specific service utilization at the HCTC
were collected prospectively from patient files kept at the
centre. Data on service utilization at hospitals in Western
Cape were collected retrospectively from paper-based
medical records at the relevant hospitals. Where such files
were not available, the lengths of stay and laboratory tests
performed were identified from less detailed, computer-
ized records. Ethical approval for this study was gained
from the University of Cape Town Research Ethics Com-
mittee and all patients gave informed consent.
Data analysis
Hospital visits were first categorized, according to the
South African Department of Health's classifications of
hospitals, into tertiary, secondary and specialist institu-BMC Health Services Research 2007, 7:80 http://www.biomedcentral.com/1472-6963/7/80
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tions. Hospital visits were second categorized according to
the primary reason for seeking care, based on information
available from patient's files. Visits were separated into
those due to: (i) HIV-related illness, by OI; (ii) adverse
reactions to antiretrovirals, by probable causative drug;
(iii) health problems unrelated to HIV, by primary site of
illness; and (iv) investigations of symptoms.
Visits were further categorized into five periods by timing
relative to the commencement of ART: pre-ART; 0 to 16
weeks on ART, 17 to 32 weeks on ART, 33 to 48 weeks on
ART and all time from 49 weeks to end of follow-up. Max-
imum patient follow-up was 112 weeks on ART. Visit rates
were calculated as numbers of outpatient visits and inpa-
tient days per 100 patient years of observation (PYO).
Continuous data were described using medians and inter-
quartile ranges (IQRs); categorical data using counts and
percentages. Differences in continuous data were evalu-
ated using the Rank-Sum test; trends in rates were evalu-
ated using the Cochran-Armitage test. All tests were two-
sided at α = 0.05.
Results
Study population and overall utilization
253 persons were screened at the clinic in 2002 and 2003.
Prior to ART commencement 41 persons were either lost
to follow-up or excluded as not meeting the eligibility
requirements. The study population thus consisted of 212
patients, whose baseline demographic, clinical and viro-
logical characteristics are described in Table 1. Twelve
patients died prior to commencing ART, 200 patients
started ART, 172 were followed-up to 48 weeks and 132 to
at least 64 weeks. The median period of follow-up pre-
ART was 30 days (IQR 28–50) and on ART was 448 days
(IQR 336–672).
During the 279 patient-years observed, 2573 outpatient
visits and 1494 inpatient days, consisting of 109 separate
admissions, were recorded (Table 2). One tertiary, four
secondary and one dedicated tuberculosis hospital were
attended. The overall rate of visits, excluding scheduled
primary-care ART monitoring visits, fell from 596 per 100
PYO in the pre-ART period to 334 per 100 PYO during the
first 48 weeks on ART and further to 245 per 100 PYO
thereafter. The total rate of inpatient days also fell from
2549 days per 100 PYO prior to starting ART to 476 days
per 100 PYO in the first 48 weeks and 73 days per 100
PYO subsequently.
In the pre-ART period 65 patients (31%) made an
unscheduled primary-care visit, 19 (9%) had attended a
secondary care clinic and 14 (7%) had appointments at
the tertiary level. Five (2%) of patients had a tertiary inpa-
tient episode in the period prior to commencing ART and
18 (9%) had a secondary inpatient visit. During the 48
weeks on ART 128 (61%) patients made unscheduled vis-
its to the HCTC, while only 26 (13%) attended secondary
clinics and 32 (16%) attended tertiary clinics. Forty-one
(21%) patients had a secondary inpatient episode during
their first 48 weeks on ART and 14 (7%) had a tertiary
inpatient episode. A summary of causes of hospital utili-
zation is provided in Table 3.
Outpatient care
The vast majority (89%) of all outpatient visits were made
to the primary healthcare provider, the HCTC. Of these,
almost three-quarters (72%) were scheduled visits, falling
most heavily in the periods pre- and immediately post-
initiation of ART. Once commenced on ART the rate of
both scheduled and unscheduled visits fell until 17 to 32
weeks on ART, after which they stabilized. The rate of both
types of visit had a downward trend (χ2 = 517 & χ2 = 41.6,
p < 0.001).
Secondary outpatient visit rates were highest prior to com-
mencement of ART, falling rapidly once ART began; there
was a significant downward trend in these rates (χ2 = 10.0,
p < 0.002). Once ART had commenced, the majority of
visits were for HIV-related illnesses up to 32 weeks (Figure
1a). From 32 to 48 weeks on ART over half of visits (58%)
were for ART-related illnesses relating to stavudine, either
lactic acidosis or peripheral neuropathy. After 48 weeks
on ART most visits (61%) were for non-HIV-related mat-
ters.
Table 1: Demographic, clinical and virological characteristics on 
admission to program
Age, median (IQR) in years 33 (29–38)
Sex
Female 153 (72.5)
Male 58 (27.5)
WHO clinical stage
1 or 2 22 (10.4)
3 (Symptomatic) 97 (45.8)
4 (AIDS) 93 (43.8)
CD4 count (cells/µl)
≤ 50 66 (31.3)
51 – 100 58 (27.5)
101 – 200 71 (33.6)
> 200 16 (7.6)
HIV RNA (copies/ml)
≤ 1000 3 (1.5)
1001 – 10 000 13 (6.4)
10 001 – 100 000 91 (45.1)
> 100 000 95 (47.3)
Figures are numbers (percent) unless otherwise stated. N = 212.B
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Table 2: Distribution of visits within the cohort: rates per 100 patient-years of observation (absolute numbers in parentheses)
Outpatient Visits Inpatient Stays
Period on ART Initial no. of 
Patientsa
Patient 
Years
Deaths Losses to 
Programb
HCTC 
Unscheduled
HCTC 
Scheduled
Tertiary Total Tertiary Secondary Tuberculosis Total Patients with no 
inpatient stay (%)
Pre-treatment 211 25 48
(12)
382
(96)
1662
(418)
115
(29)
2258 243
(61)
225
(64)
2051
(516)
2549 89
0–16 weeks 200 58 26
(15)
7
(4)
312
(181)
996
(557)
86
(50)
1427 294
(170)
478
(277)
130
(75)
902 83
17–32 weeks 181 55 4 
(2)
7
(4)
174
(95)
331
(181)
59
(32)
593 187 
(102)
31
(17)
218 94
33–48 weeks 175 53 6
(3)
211
(112)
352
(187)
55 
(29)
654 75
(40)
186
(99)
15
(8)
276 91
49–64 weeks 132 89 2
(2)
1
(1)
173
(153)
328 
(290)
46
(41)
573 38
(34)
35
(31)
73 94
65–80 weeks 89
81–96 weeks 54
97–112 weeks 15
Total 212 279 12
(34)
3
(9)
228
(637)
592
(1653)
63
(181)
920 148
(407)
175
(488)
214
(599)
537 62
Figures presented in the text may not be precisely reproducible from the data provided due to rounding. a One patient commenced ART at her first visit and therefore does not appear in the Pre-treatment 
period. b Losses to program consisted of eight losses to follow-up and one transfer out occurring at 0–16 weeks.BMC Health Services Research 2007, 7:80 http://www.biomedcentral.com/1472-6963/7/80
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The rate of tertiary outpatient visits was highest prior to
ART, declining to a plateau after 32 weeks on ART. The
majority of these visits from screening to 48 weeks on ART
were for HIV-related illnesses; after 48 weeks this propor-
tion declined to a third of the total. The single largest
cause of HIV-related visits was treatment of Kaposi's sar-
coma and other cancers (39%) while the largest cause of
non-HIV-related visits was ophthalmic complaints
(25%). Like all other inpatient and outpatient categories,
tertiary visit rates declined over time (χ2 = 15.6, p <
0.001).
Inpatient care
There was a downward trend in the overall rate of inpa-
tient days (χ2 = 1463, p < 0.001). A large proportion of all
secondary care inpatient days were due to HIV-related ill-
ness up to 32 weeks on ART (Figure 1b). Key causes were
tuberculosis and bronchietasis (41%) and Cryptococcal
meningitis (31%). This burden of HIV-related care over-
lapped with stavudine-related illness, which accounted
for 46% of all secondary inpatient days between 17 and
48 weeks on ART. After 48 weeks on ART the large major-
ity (90%) of care was due to non-HIV-related illness.
The majority of tertiary inpatient time over the first three
periods of observation was due to HIV-related illness.
Over half (56%) of all these days were due to one patient
being treated for Burkitt's lymphoma. One fifth of all
inpatient time in first 16 weeks on ART was due to two
patients, one suffering an adverse reaction to efavirenz,
the other to nevirapine, although this latter stay was
extended by a nosocomial infection. Between 32 and 48
weeks almost half (48%) of all tertiary inpatient care was
due one patient suffering from an adverse reaction to sta-
vudine. Once more, after 48 weeks on ART most inpatient
care (84%) was for non-HIV-related issues.
Table 3: Summary of major causes of hospital care utilization prior to and on ART
Outpatient visits Inpatient days
Hospital type Secondary Tertiary Total (%) Secondary Tertiary Total (%)
Tuberculosis & Bronchiectasis 6 703 1
Other bacterial infections 4 7 40 12
Cryptococcal Meningitis 14 90 42
Other fungal infections 7 3 28
Kaposi's sarcoma 33
Other HIV-related neoplasms 1 8 173
Protozoan infections 3 3 19 23
Warts 10 11
CMV Retinitis 15 4
Other Viral infections 1 15 1 5
Other HIV-related events 2 10 17
All HIV-related events 142 (50) 1168 (78)
Efavirenz reaction 51 3
Nevirapine reaction 12 1
Stavudine reaction 11 56 19
All ART drug reactions 11 (4) 115 (8)
Investigations 2 14 14 (5) -
Antenatal care 4 8 7 21
Gynecological 7 9
Hepatic 6 12 16 6
Ophthalmic 19 5
Cardio-vascular 5 46
Other 24 31 75 26
All non-HIV-related events 116 (41) 211 (14)
Total 102 181 1087 407
1 Includes admissions to specialist tuberculosis hospital. 2 Cause remained uncertain after investigation.BMC Health Services Research 2007, 7:80 http://www.biomedcentral.com/1472-6963/7/80
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There were six admissions to the specialist tuberculosis
hospital prior to ART commencement, with a mean stay of
86 days; a further two admissions arose on ART, with a
mean stay of 42 days. These admissions accounted for
40% of all inpatient days recorded.
An analysis excluding the eight patients attending the ded-
icated tuberculosis hospital and the four patients individ-
ually identified as the heaviest users of services above still
found a downward trend in service utilization over time.
The rate of inpatient days fell to 496 per 100 PYO in the
pre-ART period and to 506 per 100 PYO in the first 16
weeks on ART. Thereafter rates were similar to the main
results. A sub-analysis looking at those 12 patients who
died prior to commencing ART found their use of inpa-
tient services to be far greater than other patients (16,128
versus 1954 days per 100 PYO in the pre-ART period).
Their use of outpatient services was, however, almost
identical to the cohort as a whole in the period (569 ver-
sus 597 visits per 100 PYO).
Discussion
The patients in this community-based ART program had a
high demand for healthcare services immediately prior to
and post initiation of ART. Demand for healthcare fell as
time after ART commencement increased, although terti-
ary and secondary inpatient days (excluding dedicated
tuberculosis care) rose briefly in the first four months on
treatment. The fall in inpatient care mirrors that seen else-
where, but the fall in outpatient care is in contrast to find-
ings both in North America and in a hospital-based ART
program in South Africa [21,22]. Removing the frequent
scheduled primary care visits required prior to commence-
ment does not reverse this latter effect.
Although the clinical characteristics of these patients are
not identical to those reported from North America, a
comparison may be instructive. The rates of utilization
seen in this population prior to ART initiation, both for
inpatient days (2258 per 100 PYO) and outpatient visits
(2549 per 100 PYO), were far higher than those reported
elsewhere [12-14]. On ART, outpatient utilization (920
visits per 100 PYO) was comparable to North American
rates, although inpatient demand (537 days per 100 PYO)
was almost double that seen elsewhere. Given the high
levels of viral suppression in this population [23], this
higher rate of utilization is unlikely to reflect poor viral
suppression. It may, however, reflect either the more
advanced illness in this population at ART commence-
ment compared to North American ones, or higher levels
of exposure to pathogens in the South African environ-
ment.
The utilization of hospital services in this sample was
unbalanced: the proportion of patients using inpatient
services, shown in Table 3, was low in all periods, and
almost two-thirds of patients had no inpatient stay. A
small number of patients with HIV-related illnesses which
arose prior to 32 weeks on ART were responsible for the
majority of the inpatient utilization. Six individuals
treated for tuberculosis as inpatients accounted for 81% of
all inpatient days pre-ART; two patients with lymphomas
consumed 43% of all tertiary inpatient care recorded.
Other sizeable causes of hospital care use included Cryp-
tococcal meningitis, Kaposi's sarcoma and cytomegalovi-
rus-related retinitis. Tuberculosis and bronchiectasis
accounted for 47% of all inpatient days and other AIDS-
defining illnesses a further 28%.
Breakdown at each hospital level by cause of demand of (a)  outpatient visits and (b) inpatient days Figure 1
Breakdown at each hospital level by cause of demand of (a) 
outpatient visits and (b) inpatient days.
A 
HIV
ARV
Other
Investigations
HIV
ARV
Other
Investigations
HIV
ARV
Other
Investigations
The surface area of each pie is proportional to the rate of  outpatient visits 
Weeks on ART
Pre-Treatment 0-16 33-48 17-32 49-112
Secondary Inpatient Days
Tertiary Inpatient Days
HIV
ARV
Other
Investigations
HIV
ARV
Other
Investigations
HIV
ARV
Other
Investigations
The surface area of each pie is proportional to the rate of  outpatient visits 
Weeks on ART
Pre-Treatment 0-16 33-48 17-32 49-112
Secondary Inpatient Days
Tertiary Inpatient Days
B 
The surface area of each pie is proportional to the rate of inpatient days 
Weeks on ART
Tertiary Inpatient Days
HIV
ARV
Other
Secondary Inpatient Days
Pre-Treatment 0-16 33-48 17-32 49-112
The surface area of each pie is proportional to the rate of inpatient days 
Weeks on ART
Tertiary Inpatient Days
HIV
ARV
Other
Secondary Inpatient Days
Pre-Treatment 0-16 33-48 17-32 49-112BMC Health Services Research 2007, 7:80 http://www.biomedcentral.com/1472-6963/7/80
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Given this unbalanced distribution of utilization, an
intervention that could pinpoint and intensively monitor
patients likely to require hospital services might reduce
utilization through early treatment of serious conditions.
Although overall utilization of hospital services was
higher in almost all periods for those patients with low
baseline CD4 counts (Table 4), there was no significant
difference in baseline CD4 count, viral load or WHO stage
between those who did and did not access hospital serv-
ices in this population (not shown).
A more proactive intervention would be to initiate ART
prior to the onset of clinical symptoms, and thus decrease
utilization by reducing the incidence of OIs. In South
Africa, the incidence of tuberculosis among HIV infected
individuals rises above that seen in the rest of the popula-
tion once CD4 counts fall below 350 cells/µl [24], and
ART reduces this incidence by up to 90% [25,26]. This
suggests that commencing ART earlier than the current
guideline of less than 200 cells/µl could significantly
reduce the proportion of ART-commencing patients
requiring acute treatment. The argument is further sup-
ported by the observation above that late commencement
of ART appears to be associated with increased demand
for inpatient care.
Between 33 and 48 weeks on ART, HIV-related demand
fell, but there was a rise in service utilization for ART-
related illness. In particular, seven patients suffered from
either lactic acidosis or peripheral neuropathy, attributed
to stavudine, which was severe enough to cause them to
visit a hospital, six of them as inpatients. The use of stavu-
dine as a first-line therapy in South Africa is the product of
cost constraints. The evidence in this setting suggests that
the resource requirements associated with stavudine-
related illness may offset some or all of the cost benefits of
using stavudine. After twelve months on ART, both HIV-
related and ART-related illnesses diminished.
There are a number of limitations inherent to the design
of this study. First, the sample size of 212 persons is small,
particularly given the skewed nature of the data. The pos-
sibility that the patterns seen are driven by a few outlying
values cannot be entirely dismissed. Furthermore, the
two-year follow-up of this study means that little can be
said about the possible displacement of healthcare
demand to future periods. Finally, the short pre-ART
observation period may have made these results sensitive
to patients' recent prior medical history. This latter effect
may have been to overestimate demand, if referral to the
HCTC was because of recent OI diagnosis, or to underes-
timate it, if referral followed a recent hospital discharge.
These limitations are at least partly the result of the retro-
spective nature of the study. The inclusion of prospective
hospital utilization studies in ART program monitoring
and evaluation processes would ensure more data was col-
lected over a longer period of time, allowing more robust
conclusions to be drawn.
Several other factors may affect the generalizability of
these findings to persons eligible for ART nationally, and
across sub-Saharan Africa. Admission to the program
depended on standard national public-sector inclusion
criteria and care was provided through a clinic at public-
sector, primary-care site. However, since this was the first
clinic to make ART available in the district, those referred
are likely to have been sicker than the eligible population
on average, overestimating the level of care required. As
the national program is rolled-out the nature of the pro-
gram, and thus the utilization pattern of patients, may
change. Furthermore, this population had better access to
healthcare than most persons living in high HIV-burden
areas due to its proximity to a major city and tertiary
health services.
Conclusion
Despite these limitations, the evidence of this study sug-
gests that starting patients on ART, even when their illness
is advanced, can lead to a significant and rapid fall in
healthcare demand, particularly for HIV-related illnesses.
It further suggests that earlier commencement might
avoid the cost of treating many of the OIs seen in this pop-
ulation.
Table 4: Comparison of overall hospital inpatient and outpatient visit rates stratified by CD4 count
CD4 count ≤ 50 cells/µl CD4 count > 50 cells/µl
Period on ART Initial no. of 
Patients
Inpatient 
Days/100 PYO
Outpatient 
Visits/100 PYO
Initial no. of 
Patients
Inpatient Days/100 PYO Outpatient Visits/100 PYO
Pre-treatment 67 3838 253 144 1945 199
0–16 weeks 61 1315 182 139 691 93
17–32 weeks 51 53 112 130 281 79
33–48 weeks 47 645 132 128 139 75
49–112 weeks 38 214 109 94 16 57
CD4 count refers to that recorded at admission to program. PYO: Patient years of observation.Publish with BioMed Central    and   every 
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